Introduction {#S1}
============

Invasive candidiasis (IC) is an important fungal disease among hospitalized patients, associated with significant mortality and excessive medical costs ([@B20]). Although *Candida albicans* still overall accounts for the majority of IC, many studies have reported increased prevalence of infections caused by non-*C. albicans* species ([@B4]; [@B36]; [@B24]). Particularly, the incidence of *C. parapsilosis* infection is increasing among hospitalized patients and has become one of the main pathogens causing candidemia in certain geographical areas including China ([@B16]; [@B24]; [@B28]; [@B38]). The National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) program is an ongoing nationwide, multicenter surveillance network established in July 2009 to provide data on the epidemiology of invasive fungal infections in China ([@B45]; [@B47], [@B48]). In the period from 2010 to 2015, *C. parapsilosis* was the second most common species isolated from bloodstream after *C. albicans* (32.3%), accounting for 28.9% of cases ([@B48]).

Of note, during the ongoing program, there was a large increase in the rates of isolation of *C. parapsilosis* in hospital H01 in 2016 (*n* = 47) compared to 2015 (*n* = 7), which alerted us to a potential outbreak of infection in this hospital. *C. parapsilosis* is well established as a cause of nosocomial fungemia outbreaks, particularly in neonatal intensive care units (NICUs) ([@B17]; [@B22]; [@B23]; [@B33]; [@B21]; [@B1]). Outbreaks have been reported in diverse geographical regions, with most outbreaks occurring in NICUs and ICUs ([@B15]; [@B19]; [@B11]; [@B3]; [@B17]; [@B44]; [@B10]; [@B22]; [@B29]; [@B27]; [@B21]). In addition, there have been reports of clonal transmission involving fluconazole-resistant strains in Brazil and India ([@B40]; [@B37]). Of the three species of *C. parapsilosis* complex, (*C. parapsilosis* sensu stricto, *C. orthopsilosis*, and *C. metapsilosis*), most data on outbreaks have focused on *C. parapsilosis* sensu stricto ([@B39]). In China, however, there are relatively few descriptions of outbreaks of *C. parapsilosis* and accompanying molecular epidemiology investigations ([@B46]; [@B30]).

Based on the unexpected observation of potential case clusters in the CHIF-NET study above, the present study aimed to present the findings of the molecular epidemiology of *C. parapsilosis* sensu stricto isolates obtained from patients from 10 hospitals surveyed between August 2015 and July 2017. We chose to use a four-locus microsatellite-based typing method to genotype *C. parapsilosis* sensu stricto isolates described by [@B34] as this method has proven to be of good discriminatory (power of 99.9%), and is a common tool for genotyping *C. parapsilosis* sensu stricto ([@B44]; [@B33]; [@B7]; [@B35]). We used these microsatellite markers to distinguish isolates from all participant hospitals, aiming to uncover the endemic genotypes in different hospitals, and to call genetic association to support epidemiologically linked isolates in case clusters.

Materials and Methods {#S2}
=====================

Isolates {#S2.SS1}
--------

A total of 319 non-duplicate *C. parapsilosis* isolates cultured from 319 patients with IC were collected from 10 hospitals in the CHIF-NET program 2016 and 2017 \[hospitals H01 (*n* = 98 isolates), H02 (*n* = 22), H03 (*n* = 25), H04 (*n* = 18), H05 (*n* = 19), H06 (*n* = 26), H07 (*n* = 16), H08 (*n* = 36), H09 (*n* = 8), and H10 (*n* = 51)\]. The 10 hospitals were located at different districts across China, including Beijing, Fujian, Guangzhou, Henan, Hubei, Jilin, Liaoning, Shaanxi, Shanghai, and Sichuan. Among the 319 patients, there were 24 who had isolates cultured simultaneously from blood as well as from the tip of vascular catheters which had been *in situ.* The 24 strains from the catheter tips were genotyped in addition to the blood isolates, to determine if they shared the same genotype.

All strains were forwarded to a central laboratory (The Department of Clinical Laboratory, Peking Union Medical College Hospital) for confirmation of species identification by using the Vitek MS system (BioMerieux, France) selectively supplemented by ribosomal DNA sequencing as required ([@B45]; [@B49]). The program was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (S-263).

Antifungal Susceptibility Testing {#S2.SS2}
---------------------------------

*In vitro* antifungal susceptibility to nine antifungal drugs was performed using the Sensititre YeastOne^TM^ YO10 system (Thermo Scientific, Cleveland, OH, United States) following the manufacturer's instructions. The quality control strains included *C. parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258. MIC values of anidulafungin, micafungin, caspofungin, voriconazole, and fluconazole were interpreted according to current Clinical and Laboratory Standards Institute (CLSI) M60 clinical breakpoints ([@B5]). Where there are no CLSI breakpoints, species-specific epidemiology cutoff values (ECVs) were used to define isolates as wild type (WT) or non-wild type (NWT) for amphotericin B, posaconazole, itraconazole, and flucytosine ([@B25]; [@B6]).

Microsatellite Typing {#S2.SS3}
---------------------

Genotyping of all *C. parapsilosis* isolates was performed using a panel of four highly polymorphic microsatellite markers as described by [@B34], namely B5, CP1, CP4, and CP6. Amplification reactions and allele sizes analysis were performed as previously reported ([@B46]). The genetic relationships between the genotypes were studied by constructing a minimum spanning tree using the BioNumerics software v7.6 (Applied Maths, Sint-Martens-Latem, Belgium), treating the data as categorical information. Genotypes showing the same alleles for all four markers were considered identical. Endemic genotypes were defined as genotypes infecting ≥2 different patients in one hospital. A cluster was defined as a group of ≥2 patients infected by an endemic genotype ([@B12]).

Results {#S3}
=======

Clinical Characteristics of Patients {#S3.SS1}
------------------------------------

The characteristics of patients and of *Candida* species at the different hospitals are shown in [Table 1](#T1){ref-type="table"}. For the 319 isolates, 72.7% were cultured from male patients, and 27.3% from female patients. Cases of IC included candidemia (*n* = 230), abdominal *Candida* infection (*n* = 61), central nervous system infection (*n* = 6), and other invasive infections (*n* = 22). Generally, the numbers of isolates increased with age, with 38.6% isolates from patients \>60 years. In the present study, 49.2, 11.6, and 17.9% of isolates were collected from patients located in surgical departments, medicine departments and ICUs, respectively; 2.5 and 10.3% isolates were from patients in the pediatric ward and NICUs, respectively.

###### 

Clinical characteristics of 319 patients with invasive *C. parapsilosis* infections.

  **Items**             **Total no. (%)**   **H01**   **H02**   **H03**   **H04**   **H05**   **H06**   **H07**   **H08**   **H09**   **H10**
  --------------------- ------------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  **Gender**                                                                                                                          
  Male                  232(72.7)           73        18        17        12        15        17        13        29        5         33
  Female                87(27.3)            25        4         8         6         4         9         3         7         3         18
  **Age**                                                                                                                             
  0--5                  43(13.5)            0         0         1         7         0         23        1         9         2         0
  6--20                 4(1.3)              0         1         1         1         0         0         1         0         0         0
  21--40                37(11.6)            8         1         4         0         6         0         4         7         2         5
  41--60                112(35.1)           31        14        12        7         9         2         6         13        2         16
  61--80                115(36.0)           55        4         7         3         3         1         4         7         2         29
  \>80                  8(2.5)              4         2         0         0         1         0         0         0         0         1
  **Specimen**                                                                                                                        
  Blood                 230(72.1)           74        13        8         16        13        24        6         20        7         49
  Other                 89(27.9)            24        9         17        2         6         2         10        16        1         2
  **Ward**                                                                                                                            
  Medicine              37(11.6)            9         3         4         2         7         1         4         2         2         3
  Surgical department    157(49.2)          69        9         12        5         3         1         4         12        4         38
  Pediatrics            8(2.5)              0         0         0         1         0         0         1         6         0         0
  ICU                   57(17.9)            13        9         3         4         8         1         5         3         1         10
  SICU                  16(5.0)             4         0         3         0         1         0         2         6         0         0
  NICU                  33(10.3)            0         0         1         6         0         23        0         3         0         0
  Other                 11(3.4)             3         1         2         0         0         0         0         4         1         0
  Total                 319                 98        22        25        18        19        26        16        36        8         51

ICU, intensive care unit; SICU, surgical intensive care unit; NICU, neonatal intensive care unit.

Antifungal Susceptibility of *C. parapsilosis* Isolates {#S3.SS2}
-------------------------------------------------------

The antifungal susceptibilities of the isolates are shown in [Table 2](#T2){ref-type="table"}. In general, *C. parapsilosis* was susceptible to fluconazole (94.4% susceptible), voriconazole (95.3% susceptible), posaconazole (WT isolates, 97.5%), and itraconazole (WT isolates, 100%). Sixteen fluconazole-resistant isolates were from hospitals H02 (*n* = 7), H04 (*n* = 3), H08 (*n* = 4), H09 (*n* = 1), and H07 (*n* = 1). All 319 isolates were susceptible to echinocandins and had WT MICs to amphotericin B except for two isolates which were classed as moderately susceptible to micafungin (MIC, 4 μg/mL). For 5-flucytosine, 37 (11.6%) isolates had NWT MICs, largely from hospital H01 (*n* = 32 isolates), and the rest from hospitals H04 (*n* = 3) and H08 (*n* = 2).

###### 

Antifungal susceptibility profiles of *C. parapsilosis* isolates (μg/mL).

  **Antifungals**   **MIC range**   **MIC50**   **MIC90**   **S/WT**   **R/NWT**   **Breakpoint references**
  ----------------- --------------- ----------- ----------- ---------- ----------- ---------------------------
  Anidulafungin     0.03--2         1           2           100        0           [@B5]
  Micafungin        ≤0.008--4       1           2           99.4       0           [@B5]
  Caspofungin       0.12--2         0.5         1           100        0           [@B5]
  Flucytosine       ≤0.06 -- ≥64    ≤0.06       64          88.4       11.6        [@B25]
  Posaconazole      ≤0.008--2       0.03        0.12        97.5       2.5         [@B6]
  Voriconazole      ≤0.008--4       0.015       0.06        95.3       4.7         [@B5]
  Itraconazole      ≤0.015--1       0.06        0.12        100        0           [@B25]
  Fluconazole       ≤0.12--128      0.5         1           94.4       5           [@B5]
  Amphotericin B    ≤0.12--2        0.5         1           100        0           [@B6]

S, susceptible; R, resistant; WT, wild type; NWT, non-wild type.

Microsatellite Typing (MT) of *C. parapsilosis* {#S3.SS3}
-----------------------------------------------

A total of 122 MT types for 319 isolates were identified ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). There were differences in the discriminatory power of four alleles -- allele B5 (*n* = 29, 23.8%), CP1 (23, 18.9%), CP4 (59, 48.4%), and CP6 (60, 49.2%). Among the 122 MT types, 83 genotypes were distributed sporadically. The remaining 29 genotypes were identified within 32 clusters -- MT81 formed four clusters in four different hospitals, with the remaining 28 clusters encompassing different genotypes) (see [Table 3](#T3){ref-type="table"}). In hospital H01, there were seven clusters, involving a total of 91 isolates. In H06 and H10, there were also endemic genotypes involving large number of isolates, like MT29 (*n* = 38) and MT42 (*n* = 22) ([Table 3](#T3){ref-type="table"}). The sampling interval within each endemic genotype in the same ward differed with a wide range (1--566 days). The detailed timeline and the ward information for seven endemic genotypes involving five or more isolates are shown in [Figure 1](#F1){ref-type="fig"}.

###### 

Distribution of 122 MT types in 10 hospitals.

                                   **H01**     **H02**    **H03**     **H04**    **H05**    **H06**     **H07**     **H08**    **H09**    **H10**
  -------------------------------- ----------- ---------- ----------- ---------- ---------- ----------- ----------- ---------- ---------- ----------
  No. of strains                   98          22         25          18         19         26          16          36         8          51
  No. of MT types                  14          12         18          12         13         4           15          30         6          13
  No. of strains/No. of MT types   7           1.8        1.4         1.5        1.5        6.5         1.1         1.2        1.3        3.9
  Endemic genotypes                MT95 (43)   MT70 (7)   MT81 (4)    MT81 (3)   MT81 (3)   MT42 (22)   MT114 (2)   MT81(4)    MT120(3)   MT29(38)
  in each hospital                 MT48 (29)   MT33 (3)   MT39 (2)    MT94(3)    MT79(3)                            MT22 (2)              MT21 (2)
                                   MT52 (6)    MT6 (2)    MT72 (2)    MT47(3)    MT43(3)                            MT45 (2)              
                                   MT53 (6)    MT12 (2)   MT78 (2)                                                  MT75 (2)              
                                   MT49 (3)    MT18 (2)   MT104 (2)                                                                       
                                   MT96 (2)                                                                                               
                                   MT110 (2)                                                                                              

MT, microsatellite typing.

![Timeline of the ward distribution of MT types involved in clusters of in the hospitals, of which only clusters with more than five patients infected were shown in the figure. Different colors represent different departments. Blue, surgical department; yellow, ICU; orange, medicine department; red, NICU. In hospital H06, a total of 23 isolates were collected from NICU, of which 22 isolates belonged to the genotype MT42.](fmicb-11-01320-g001){#F1}

In hospital H01, isolates from 23 patients in surgical departments, three patients in ICU, and three patients in medicine departments exhibited the endemic genotype MT48 (total *n* = 29). The MT95 genotype was evident in isolates from 43 patients -- 33 patients in surgical departments, seven patients in ICU, and three patients in medicine departments, whilst there were six isolates assigned to MT52 (four patients in surgical department and two patients in ICU) and six isolates assigned to MT53 (five patients in surgical departments and one patient in ICU). In this hospital, hence the endemic genotypes were found in different wards, though mainly in surgical wards. The MT48 first appeared in August 2015, persisted until December 2016, but appeared only one once more in June 2017. MT95, first emerged in December 2015, peaked in November 2016 (*n* = 5), and persisted until May 2017. These findings suggested the presence of potential outbreak in surgical wards, as most of the patients were infected within a short time span.

For 24 patients who had isolates cultured from blood and vascular catheter tips, the genotypes of each pair were identical in all 24 cases. Genotype data, however, from catheter isolates were not included in the phylogenetic analysis to avoid bias. The distribution of these 24 patients and the genotype data are as follows: Hospital H01 (MT48, *n* = 2; MT53, *n* = 1; MT95, *n* = 8), H02 (MT33, *n* = 1), H05 (MT43, *n* = 1; MT73, *n* = 1; MT81, *n* = 1), H06 (MT42, *n* = 3), and H10 (MT29, *n* = 4; MT68, *n* = 1; MT111, *n* = 1).

The relationship between genotypes was shown in the minimum spanning tree in [Figure 2](#F2){ref-type="fig"}. [Figure 2](#F2){ref-type="fig"} shows the genetic relationship according to different hospitals where most genotypes in each hospital are sporadically distributed. The endemic genotypes in hospital H01 were genetically closely related. The isolates from most cluster cases shared the same susceptibility pattern, except for endemic genotype MT52, one isolate from H01 showed NWT MICs to 5-flucytosine, while the remaining five isolates had WT MICs. In hospital H01, there were 29 isolates belonging to genotype MT 48, all which exhibited high MIC (\>64 μg/mL) to 5-flucytosine. Of a total of 16 fluconazole-resistant isolates, seven were from hospital H02 (all genotype MT70), and three were from hospital H04 hospital (genotype MT47).

![Minimum spanning tree showing the relationship of 122 MT types among 319 isolates distributed in ten hospitals. Each circle represents a unique genotype. The size of the circle corresponds to the number of isolates of the specific genotype. Different colors represent different hospitals. Fluconazole resistant isolates were distributed in genotypes MT15 (H08, *n* = 1), MT47 (H04, *n* = 3), MT48 (H09, *n* = 1), MT50 (H08, *n* = 1), MT70 (H02, *n* = 7), MT75 (H08, *n* = 2), and MT114 (H07, *n* = 1). 5-flucytosine NWT strains were distributed in genotypes MT45 (H08, *n* = 2), MT48 (H01, *n* = 29), MT52 (H01, *n* = 1), MT88 (H04, *n* = 1), MT96 (H01, *n* = 2), MT97 (H04, *n* = 1), MT106 (H04, *n* = 1).](fmicb-11-01320-g002){#F2}

Discussion {#S4}
==========

*Candida parapsilosis* has been reported to be a significant clinical pathogen, being able to form biofilms on central venous catheters and other medically implanted devices, and which can persist in the hospital environment. This last characteristic gives propensity for this fungus to cause nosocomial case clusters via carriage on hands of staff ([@B42]; [@B43]; [@B41]). In the present study, we used microsatellite genotyping method to study the molecular epidemiology of *C. parapsilosis*, cultured from patients with invasive fungal infections, as part of the national surveillance program CHIF-NET 16-17. We chose to use microsatellite typing as this method has emerged as a powerful tool to study the genetic relationship between *C. parapsilosis* isolates in the outbreak setting ([@B44]; [@B10]; [@B29]; [@B32]; [@B33]; [@B7]; [@B35]; [@B46]; [@B2]; [@B21]; [@B8]).

Data for 319 patients were analyzed; of these 230 patients suffered from candidemia. The patients were mainly adults from surgical departments and ICUs, except for the patients in hospital H06 hospital (mainly NICU). By microsatellite typing, we uncovered 32 cluster cases in 10 hospitals during a period of 2 years. The timeline of cluster cases indicates that certain endemic genotypes have persisted in the hospital setting, and presumably were difficult to eradicate, consistent with previous reports ([@B12], [@B13]). [@B46] previously reported details of a *C. parapsilosis* outbreak in China, where 97 isolates comprising only two clones were mainly obtained from the ICU and surgical wards. Other *C. parapsilosis* outbreaks in ICUs have been reported from countries such as Brazil and Turkey ([@B11]; [@B27]). Notably, in the present study, strains of the MT42 genotype were responsible for a 22-case cluster in the NICU of hospital H06 ([Figure 1](#F1){ref-type="fig"}); previously, case clusters in NICUs have been uncommonly reported in China. *C. parapsilosis* has been recognized as a significant pathogen in NICUs worldwide ([@B41]). A meta-analysis of neonatal candidiasis by [@B23] showed that *C. parapsilosis* comprised 33.5% of all neonatal *Candida* infections, and was associated with 10% mortality. Not unexpectedly, in the 24 patients from whom *C. parapsilosis* isolates were cultured simultaneously from blood and catheter tips, the isolates all exhibited the same genotype, consistent with the widely accepted notion that vascular catheters often represent the source of candidemia and the meticulous catheter care is important for source control ([@B13]).

Notably, there were fluconazole resistant isolates responsible for the case clusters in the present study, particularly in two hospitals (three isolates from patients in hospital H04 and seven from patients in H02 hospital). Others have reported clonal emergence or outbreaks of fluconazole-resistant isolates of *C. parapsilosis* ([@B27]; [@B40]; [@B37]). Hence such clusters should signal an alert to clinicians and microbiologists alike. Raghuram et al. have reported that fluconazole-resistant strains of *C. parapsilosis* may be more pathogenic than fluconazole-susceptible strain in liver transplant patients ([@B31]). In another report, a patient infected with azole-resistant *C. parapsilosis* died despite appropriate antifungal treatment ([@B50]). Overall, however, only 5% of *C. parapsilosis* isolates were resistant to fluconazole in the present study compared with 3.9% in the SENTRY program ([@B26]). Despite being overall uncommon, resistance of *C. parapsilosis* to fluconazole has been increasing reported, and the data from SENTRY Program suggest that fluconazole-resistant *C. parapsilosis* could emerge in the presence of drug pressure during fluconazole treatment and prophylaxis, with subsequent transmission between patients in the hospital environment ([@B26]).

Of equal concern, in hospital H01, there were clonal clusters of a 5-flucytosine NWT *C. parapsilosis* strain (MT48, *n* = 29), indicating an unrecognized *C. parapsilosis* cluster case due to a flucytosine NWT isolate, another rare event in China. 5-flucytosien NWT strains have been reported for *Candida tropicalis* in France ([@B9]). [@B47] reported in CHIF-NET 2010-12 that only 0.8% *C. parapsilosis* species complex were NWT to 5-flucytosine, and all isolates were inhibited at drug concentrations of ≤1 mg/L. In contrast, in the present study 11.6% isolates were NWT to 5-flucytosine, and were mainly distributed in hospital H01 with the MIC NWT isolates ≥64 mg/L. 5-flucytosine is typically used in combination with other antifungals. The combination of 5-flucytosine and azoles or amphotericin B remains primary treatment for *Candida* meningitis or endocarditis ([@B18]; [@B14]). The emergence of 5-flucytosine NWT isolates in the outbreak setting poses the question of whether resistance may be transmitted between patients like fluconazole-resistant isolates.

There were some limitations to this study. First, information of clinical characteristics, risk factors, and outcomes of patients with *C. parapsilosis* infections and those associated with the cluster cases were not available. Second, the study was performed retrospectively, and we could not collect the isolates from the hospital environment or health care workers' hands, thus it was not possible to identify the mode of transmission. Third, there was no data about patients transferring between different wards within the hospitals, as well as the rotation of healthcare workers between different departments, and therefore this limited the explanation as to why there were certain endemic genotypes existing in different areas within any one hospital. Further work is needed to investigate the clinical and microbiological consequences of the current cluster cases, especially in hospitals H01, H06, and H10.

Nonetheless the present study was instructive in that it brought to light, several nosocomial cluster cases of *C. parapsilosis* infection including those involving azole-resistant strains. Lack of awareness of healthcare-associated infections and transmission, particularly those caused by fungi, is common in hospitals in China. Increasing candidemia morbidity and emergence of azole-resistant *Candida* species serve to emphasize the attention required for effective management of *Candida* infections including strategies for infection control.
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